This Edition
ARTICLE | Product Development
GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute
Plus SAB gets additional funding from U.S. government, starts human trials
By Sandi Wong, Assistant Editor
August 13, 2020 1:48 AM UTC
Access this Article
Request a Trial
Purchase This Article
Log in
BCIQ Company Profiles
SAB Biotherapeutics Inc.
GigaGen Inc.
BCIQ Company Profiles
SAB Biotherapeutics Inc.
GigaGen Inc.